The first patients have been dosed in a phase 3 trial of an mRNA-based seasonal influenza vaccine developed by Pfizer and BioNTech, which may offer quicker production and greater efficacy than ...
Researchers recently developed a new approach for identifying new cellular RNA targets of snoRNAs. They uncovered thousands of previously unknown targets for snoRNAs in human cells and mouse brain ...